NCT05896865View on ClinicalTrials.gov

Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

March 16, 2028

Study Completion Date

March 16, 2030

Conditions
Breast Cancer Stage III
Interventions
RADIATION

Whole breast / chest wall & regional lymph node irradiation

Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions

RADIATION

Internal mammary or supraclavicular lymph node boost

Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER